Skip to main content

EGFR-IN-11 (C09-1130-582)

Aladdin

Catalog No.
C09-1130-582
Manufacturer No.
E647319-25mg
Manufacturer Name
Aladdin Scientific
Quantity
1
Unit of Measure
EA
Price: $1,670.07
List Price: $1,855.63

EGFR-IN-11 is a fourth-generation EGFR -tyrosine kinase inhibitor ( EGFR-TKI ) with an IC 50 of 18 nM for triple mutant EGFR L858R/T790M/C797S . EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis , and arrest cell

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Adding to cart… The item has been added
EGFR-IN-11 is a fourth-generation EGFR -tyrosine kinase inhibitor ( EGFR-TKI ) with an IC 50 of 18 nM for triple mutant EGFR L858R/T790M/C797S . EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis , and arrest cell cycle at G0/G1In VitroEGFR-IN-11 (Compound D9; 0.0001-10 µM; 72 hours) shows significantly potent anti-proliferation against HCC827 and H1975 cell lines with IC 50 s of 0.88 nM and 0.20 µM, respectively. EGFR-IN-11 (0.01-1.00 µM for HCC827 cells; 0.1-10.00 µM for H1975 and A549 cells; 8 hours) suppresses EGFR phosphorylation in a concentration-dependent manner in the HCC827, H1975 and A549 cell line. EGFR-IN-11 (1 µM; 24 h) potently induces the apoptosis of HCC827 cells.EGFR-IN-11 (1 µM; 24 h) induces cell cycle arrests in HCC827 cell. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Human lung cancer cell lines HCC827 (EGFR Del E746-A750 ), H1975 (EGFR L858R/T790M ) and A549 (EGFRWT); epidermoid carcinoma cell line A431 (EGFRWT) Concentration: 0.0001, 0.0003, 0.001, 0.003, 0.01, 0.1, 1, 10 µM Incubation Time: 72 hours Result: Inhibited HCC827 H1975 A549 cells proliferation with IC 50 s of 0.88±0.09 nM, 0.20±0.01 μM, 2.91±0.61 μM, and >10 μM, respectively. Western Blot AnalysisCell Line: HCC827, H1975 and A549 cells Concentration: 1.00, 0.10 and 0.01 µM for HCC827 cells; 10.00, 1.00 and 0.10 µM for H1975 and A549 cells Incubation Time: 8 hours Result: Suppressed EGFR phosphorylation in a concentration-dependent manner. EGFR phosphorylation in the HCC827 cell line was more remarkably suppressed than in the H1975 and A549 cell lines. Apoptosis AnalysisCell Line: HCC827 cells Concentration: 1 µM Incubation Time: 24 hours Result: The percentages of apoptotic cells is 56.91%. Cell Cycle AnalysisCell Line: HCC827 cells Concentration: 1 µM Incubation Time: 24 hours Result: The number of HCC827 cells in G0/G1 phase was increased significantly.Form:SolidIC50& Target:EGFR L858R/T790M/C797S 18 nM (IC 50 ). Specifications and Purity: 99%. Molecular Formula: C29H35N9O2S. Molecular Weight: 573.71.
UPC:
12352005
Condition:
New
Availability:
8-12 weeks
Weight:
1.06 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
E647319-25mg
CAS:
2463200-44-2
Product Size:
25mg


Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.


"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR


"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER


"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN


"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.